% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Freitag:125848,
      author       = {M. Freitag$^*$ and J. P. Radtke$^*$ and B. A. Hadaschik and
                      A. Kopp-Schneider$^*$ and M. Eder$^*$ and K. Kopka$^*$ and
                      U. Haberkorn$^*$ and M. Röthke$^*$ and H.-P. Schlemmer$^*$
                      and A. Afshar-Oromieh$^*$},
      title        = {{C}omparison of hybrid (68){G}a-{PSMA} {PET}/{MRI} and
                      (68){G}a-{PSMA} {PET}/{CT} in the evaluation of lymph node
                      and bone metastases of prostate cancer.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {43},
      number       = {1},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2017-01972},
      pages        = {70 - 83},
      year         = {2016},
      abstract     = {To evaluate the reproducibility of the combination of
                      hybrid PET/MRI and the (68)Ga-PSMA-11 tracer in depicting
                      lymph node (LN) and bone metastases of prostate cancer (PC)
                      in comparison with that of PET/CT.A retrospective analysis
                      of 26 patients who were subjected to (68)Ga-PSMA
                      PET/CTlow-dose (1 h after injection) followed by PET/MRI
                      (3 h after injection) was performed. MRI sequences included
                      T1-w native, T1-w contrast-enhanced, T2-w fat-saturated and
                      diffusion-weighted sequences (DWIb800). Discordant
                      PET-positive and morphological findings were evaluated.
                      Standardized uptake values (SUV) of PET-positive LNs and
                      bone lesions were quantified and their morphological size
                      and conspicuity determined.Comparing the PET components, the
                      proportion of discordant PSMA-positive suspicious findings
                      was very low $(98.5 \%$ of 64 LNs concordant, $100 \%$ of
                      28 bone lesions concordant). Two PET-positive bone
                      metastases could not be confirmed morphologically using
                      CTlow-dose, but could be confirmed using MRI. In 12 of 20
                      patients, 47 PET-positive LNs $(71.9 \%)$ were smaller than
                      1 cm in short axis diameter. There were significant linear
                      correlations between PET/MRI SUVs and PET/CT SUVs in the 64
                      LN metastases (p < 0.0001) and in the 28 osseous
                      metastases (p < 0.0001) for SUVmean and SUVmax,
                      respectively. The LN SUVs were significantly higher on
                      PET/MRI than on PET/CT (p SUVmax < 0.0001; p
                      SUVmean < 0.0001) but there was no significant
                      difference between the bone lesion SUVs (p
                      SUVmax = 0.495; p SUVmean = 0.381). Visibility of
                      LNs was significantly higher on MRI using the T1-w
                      contrast-enhanced fat-saturated sequence (p = 0.013),
                      the T2-w fat-saturated sequence (p < 0.0001) and the DWI
                      sequence (p < 0.0001) compared with CTlow-dose. For bone
                      lesions, only the overall conspicuity was higher on MRI
                      compared with CTlow-dose (p < 0.006).Nodal and osseous
                      metastases of PC are accurately and reliably depicted by
                      hybrid PET/MRI using (68)Ga-PSMA-11 with very low
                      discordance compared with PET/CT including PET-positive LNs
                      of normal size. The correlation between PET/MRI SUVs and
                      PET/CT SUVs was linear in LN and bone metastases but was
                      significantly lower in control (non-metastatic) tissue.},
      keywords     = {Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) (NLM Chemicals) /
                      Oligopeptides (NLM Chemicals) / Edetic Acid (NLM Chemicals)},
      cin          = {E010 / C060 / E030},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E030-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26508290},
      doi          = {10.1007/s00259-015-3206-3},
      url          = {https://inrepo02.dkfz.de/record/125848},
}